008490.KO Suheung Capsul
- Market cap
- KRW 201B
- P/E
- 5.1x
- P/B
- 0.39x
- ROE
- 9.8%
- Dividend yield
- 3.66%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 008490.KO undervalued?
Graham numberThe Graham number of Suheung Capsul cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Suheung Capsul fundamental analysis
No fundamental analysis for Suheung Capsul yet.
Suheung Capsul stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Suheung Capsul
Suheung Co., Ltd. engages in produces and sells hard and soft capsules. The company provides solid dosage forms, including hard and soft capsule, tablets, powder, granules; fluidity and concentrated liquids; gummy, sticky and water jellies. It offers medical supplies, such as prescription medicines; over-the-counter drugs comprising antipyretic-analgesics, cold medicine, digestive medicine, liver-treatment medicine, and nutritional supplements; and quasi-drugs, which include…
Full company profileSuheung Capsul financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Suheung Capsul annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 340B | 350B | 393B | 461B | 553B | 597B | 635B | 595B | 653B | 722B | 829B |
| Gross Profit | 72.4B | 72.5B | 74.3B | 91.4B | 121B | 126B | 137B | 102B | 103B | 129B | 161B |
| Operating Income | 40.1B | 37.3B | 39.3B | 47.4B | 74.3B | 69.6B | 62.0B | 43.0B | 33.8B | 50.7B | 87.5B |
| EBITDA | - | 62.7B | 69.7B | 84.3B | 115B | 121B | 98.7B | 70.1B | 92.1B | 112B | 143B |
| Net Income | 27.3B | 23.1B | 25.7B | 31.7B | 53.0B | 53.7B | 34.0B | 6.12B | 18.3B | 43.5B | 51.0B |
| EPS | - | 2,021 | 2,315 | 2,853 | 4,766 | 4,829 | 3,056 | 550 | 1,644 | 3,911 | 4,584 |
| Balance Sheet | |||||||||||
| Total Assets | 586B | 595B | 639B | 709B | 766B | 810B | 926B | 994B | 1.02T | 1.06T | 1.11T |
| Total Liabilities | 297B | 294B | 331B | 380B | 389B | 380B | 457B | 517B | 510B | 520B | 529B |
| Shareholders' Equity | 259B | 270B | 274B | 296B | 338B | 388B | 421B | 426B | 455B | 489B | 519B |
| Cash & Short-term Investments | 17.3B | 11.4B | 13.2B | 23.0B | 37.6B | 26.3B | 37.0B | 38.7B | 37.9B | 48.2B | 62.5B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 53.0B | 45.7B | 49.0B | 22.1B | 46.1B | 66.9B | 52.9B | 10.5B | 56.2B | 76.9B | 106B |
| Capital Expenditure | 38.5B | 46.6B | 60.7B | 47.5B | 52.2B | 38.1B | 64.2B | 52.3B | 38.7B | 47.3B | 50.0B |
| Free Cash Flow | - | -1.07B | -12.5B | -25.6B | -7.26B | 28.6B | -11.3B | -41.8B | 17.5B | 29.6B | 55.6B |
| Ratios | |||||||||||
| ROE | 10.5% | 8.5% | 9.4% | 10.7% | 15.7% | 13.8% | 8.1% | 1.4% | 4.0% | 8.9% | 9.8% |
| ROA | 4.7% | 3.9% | 4.0% | 4.5% | 6.9% | 6.6% | 3.7% | 0.6% | 1.8% | 4.1% | 4.6% |
| Net Profit Margin | 8.0% | 6.6% | 6.5% | 6.9% | 9.6% | 9.0% | 5.4% | 1.0% | 2.8% | 6.0% | 6.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Suheung Capsul dividends
- Dividend yield
- 3.66%
- Forward dividend
- 500.00 KRW
- Payout ratio
- 17.0%
- Ex-dividend date
- Dec 29, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 7.37B | 663 | 17.0% |
| 2024 | KRW 2.83B | 255 | 15.5% |
| 2023 | KRW 4.45B | 400 | 72.8% |
| 2022 | KRW 5.56B | 500 | 16.4% |
| 2021 | KRW 7.30B | 656 | 13.6% |
| 2020 | KRW 5.02B | 451 | 9.5% |
| 2019 | KRW 10.5B | 941 | 33.0% |
| 2018 | KRW 5.43B | 488 | 21.1% |
| 2017 | KRW 5.53B | 485 | 24.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Apr 12, 2006.
Who owns Suheung Capsul
- Insiders 58.52%
- Institutions 4.89%
- Public & others 36.59%
- Shares outstanding 11.1M
- Free float 3.58M
Suheung Capsul company profile
- Company name
- Suheung Capsul
- Ticker
- 008490.KO
- ISIN
- KR7008490005
- Exchange
- Korea Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 775
- Fiscal year end
- December
- Address
- 61, Osongsaengmyeong-ro, Cheongju-Si, South Korea
- Phone
- 82 43 249 4100
- Website
- suheung.com
About Suheung Capsul
Suheung Co., Ltd. engages in produces and sells hard and soft capsules. The company provides solid dosage forms, including hard and soft capsule, tablets, powder, granules; fluidity and concentrated liquids; gummy, sticky and water jellies. It offers medical supplies, such as prescription medicines; over-the-counter drugs comprising antipyretic-analgesics, cold medicine, digestive medicine, liver-treatment medicine, and nutritional supplements; and quasi-drugs, which includes low-content vitamin-cosmetic products, multi-vitamin, toothpaste, effervescent tablet, and chewable tablet. In addition, it provides its capsules under Embocaps brand name. The company was founded in 1973 and is headquartered in Cheongju-si, South Korea.
Suheung Capsul management
2- Mr. Joohwan YangChairperson & CEO · born 1952
- Sung-Geol YoonPresident · born 1950